Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaAcute Leukemia of Ambiguous Lineage
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: FDG-Positron Emission TomographyProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 153
- Registration Number
- NCT06317662
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Albany Medical Center, Albany, New York, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
- Conditions
- Relapsed or Refractory Follicular Lymphoma
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Target Recruit Count
- 300
- Registration Number
- NCT06313996
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
- Conditions
- Lymphoblastic LymphomaMixed Phenotype Acute LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 850
- Registration Number
- NCT06289673
- Locations
- 🇺🇸
United States, Tennessee St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 790
- Registration Number
- NCT06284122
- Locations
- 🇫🇷
HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes, Créteil, France
🇫🇷GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique, Villejuif, France
🇫🇷CH ANNECY GENEVOIS - SITE D'ANNECY - Service Hématologie, Pringy, France
Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma
- Conditions
- B-cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Target Recruit Count
- 112
- Registration Number
- NCT06251180
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
- Conditions
- High Grade B-Cell LymphomaDiffuse Large B-Cell Lymphoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission Tomography
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06249191
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Target Recruit Count
- 324
- Registration Number
- NCT06220032
- Locations
- 🇳🇱
NL-Breda-AMPHIA, Breda, Netherlands
🇳🇱NL-Almelo-ZGTALMELO, Almelo, Netherlands
🇳🇱NL-Amstelveen-AMSTELLAND, Amstelveen, Netherlands
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
- Conditions
- T Lymphoblastic LymphomaT Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Lumbar PunctureProcedure: Multigated Acquisition ScanBiological: NavitoclaxProcedure: Positron Emission TomographyProcedure: X-Ray Imaging
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT06210750
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
- Conditions
- Acute LeukemiaLymphoblastic LeukemiaLymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 33
- Registration Number
- NCT06207123
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
BV-AVD-R Treatment Children Hodgkin's Lymphoma
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Beijing Children's Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT06201507
- Locations
- 🇨🇳
Duan Yanlong, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.